OptimizeRx Corp. cash flow to debt ratio of 71.70% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

OptimizeRx Corp.'s free cash flow has increased 290.56% from $4.78M last year to $18.66M, signaling increasing performance

OptimizeRx Corp.'s debt to equity ratio is 0.18, which means that the company's assets are healthy financed, signaling financial stability.

OptimizeRx Corp.'s debt has decreased relative to shareholder equity from 0.28 last year to 0.18 today, signaling strengthened financials

OptimizeRx Corp. has a net debt to EBITDA ratio of 0.17x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

OptimizeRx Corp.'s interest coverage ratio of 2.83 indicates that earnings with margin can cover interest payments on company debt

OptimizeRx Corp.'s profit margin has increased (-129.17%) in the last year from -21.83% to 6.37%, signaling increasing performance

OptimizeRx Corp.'s short-term assets of $64.72M exceed its short-term liabilities of $21.26M

OptimizeRx Corp.'s return on assets of 4.09% is lower than the 5.00% threshold, indicating inefficient asset utilization

OptimizeRx Corp.'s return on equity of 5.47%, is lower than 15.00%, indicating bad performance

OptimizeRx Corp.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

OptimizeRx Corp. had positive net income in only 2 out of 5 years, indicating unstable earnings

OptimizeRx Corp. has positive free cash flow, indicating the company generates cash after capital expenditures

OptimizeRx Corp. has a free cash flow yield of 14.49%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

OptimizeRx Corp.'s yearly earnings has increased -125.52% since last year from $-20.11M to $5.13M, signaling increasing performance

OptimizeRx Corp.'s yearly revenue has increased 18.78% since last year from $92.13M to $109.43M, signaling increasing performance

ROIC 6.53% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

OptimizeRx Corp.'s 3-year revenue CAGR of 20.56% is positive, indicating growing revenue over the past 3 years

OptimizeRx Corp. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

OptimizeRx Corp. had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

OptimizeRx Corp. has insufficient data to evaluate this check.

OptimizeRx Corp. has an earnings yield of 5.31%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

OptimizeRx Corp. is overvalued relative to its fair value price of 5.97 based on EBITDA multiple model

OptimizeRx Corp. has an EV/EBITDA ratio of 7.93x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

OptimizeRx Corp. is overvalued relative to its fair value price of -16.59 based on Earnings Fair Value model

OptimizeRx Corp. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

OptimizeRx Corp. has a price-to-book ratio of 0.99x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

OptimizeRx Corp. has a price-to-sales ratio of 1.20x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue